Guillaumie Laurence, Moisan Jocelyne, Grégoire Jean-Pierre, Villeneuve Denis, Beaucage Clément, Bordeleau Lilianne, Lauzier Sophie
Chair on Adherence to Treatments, Université Laval, Québec, QC, Canada.
Population Health and Optimal Health Practices Unit, Centre de recherche du CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, 1050 chemin Ste-Foy, Québec, QC, G1S 4L8, Canada.
Int J Clin Pharm. 2017 Aug;39(4):686-696. doi: 10.1007/s11096-017-0502-y. Epub 2017 Jun 26.
Background Patients with an antidepressant drug treatment (ADT) report unmet needs and a significant proportion stop their ADT prematurely. Community pharmacists can play a key role in supporting these patients. Objective To explore the perspectives of various leaders in health care about the current and potential contributions of community pharmacists to patients on ADT. Setting The province of Quebec (Canada). Method We conducted a qualitative descriptive exploratory study using interviews among leaders who were involved in health care services, pharmaceutical services, physician and pharmacist education, as well as patient and healthcare professional associations. Verbatim transcripts of interviews were analyzed using computer-assisted thematic analysis. Main outcome measure Perspectives about the contributions of community pharmacists to patients on ADT. Results Interviews revealed that pharmacists are perceived to be accessible drug experts whose particular strengths are their thorough knowledge of drugs, their commitment to ensure ADT safety and tolerability, as well as their commitment to inform and support patients. Leaders trained in pharmacy or representatives of pharmacy organizations had concrete expectations for pharmacists' increased involvement in monitoring ADT adherence and efficacy. They extensively discussed the regulatory and organizational changes required to enhance this role. Leaders also stated that, in addition to patients, health care teams could benefit from pharmacists' expertise and support. Conclusion Participating key informants perceived the need for enhanced pharmacist monitoring of ADT adherence and efficacy. They also expressed their openness to an increased collaboration between health care teams and pharmacists.
接受抗抑郁药物治疗（ADT）的患者存在未满足的需求，且很大一部分患者过早停止了ADT治疗。社区药剂师可以在支持这些患者方面发挥关键作用。目的：探讨医疗保健领域各领导者对社区药剂师目前及潜在地为接受ADT治疗的患者所做贡献的看法。地点：加拿大魁北克省。方法：我们采用定性描述性探索性研究方法，对参与医疗保健服务、药学服务、医生和药剂师教育以及患者和医疗保健专业人员协会的领导者进行访谈。使用计算机辅助主题分析法对访谈的逐字记录进行分析。主要观察指标：对社区药剂师为接受ADT治疗的患者所做贡献的看法。结果：访谈显示，药剂师被视为容易接触到的药物专家，其特别优势在于对药物的全面了解、确保ADT安全性和耐受性的决心，以及为患者提供信息和支持的决心。接受过药学培训的领导者或药学组织的代表对药剂师更多地参与监测ADT依从性和疗效有具体期望。他们广泛讨论了加强这一作用所需的监管和组织变革。领导者还表示，除患者外，医疗保健团队也可从药剂师的专业知识和支持中受益。结论：参与研究的关键信息提供者认为需要加强药剂师对ADT依从性和疗效的监测。他们还表示愿意加强医疗保健团队与药剂师之间的合作。
